Chief Executive Officer
John Ripple joined Exonics Therapeutics as Chief Executive Officer in 2017. Prior to Exonics, John served as CEO of Ensemble Therapeutics, Permeon Biologics, Virdante Pharmaceuticals (acquired by Momenta Pharmaceuticals), and Syntonix Pharmaceuticals (acquired by Biogen). He also founded Ripple Biotech to advise biopharmaceutical companies on strategy, business development and capital fundraising activities. John previously held positions as entrepreneur-in-residence at the venture capital arm of Partners Healthcare as well as positions in business development at Genetics Institute and Wyeth (now Pfizer), medical device marketing, and management consulting. He started his career as an aerospace engineer at NASA. John currently serves as a member on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA), on the Board of Directors and Treasurer of the Children’s Melanoma Prevention Foundation, and as an advisor to the MIT Deshpande Center for Technological Innovation. John received a B.S. in Mechanical Engineering from Bucknell University and an MBA from Harvard Business School.